ArticleFundamental & clinical pharmacology2026
Dexamethasone-Mediated Regulation of CYP3A4 and UGTs in Human Hepatoma HuH-7 Cells.
Article in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of Uridine Diphosphoglucuronosyltransferase 2B Enzymes in Cancer Susceptibility and Treatment: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe application of human hepatic cell lines to early drug discovery and development instead of human primary hepatocytes (HPHs) has been limited because of the low level of drug-metabolizing enzymes (DMEs).
objectiveThe study aimed to evaluate the effects of dexamethasone (DEX) treatment on DME expression, activities, and regulation in HuH-7 hepatoma cells.
methodsExpression and transcriptional regulation of major CYPs and UGTs in HuH-7 cells was evaluated by immunoblotting, probe substrate assays, and treatments with nuclear receptor agonists, including DEX, and antagonists.
resultsDEX increased the expression and activity of cytochrome P450 (CYP) 3A4, uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1, and UGT2B7 but had minimal effects on CYP1A2, CYP2B6, or CYP2C9. These augmented activities of CYP3A4, UGT1A1, and UGT2B7 were concentration-dependently inhibited by their corresponding selective inhibitors. DEX-induced upregulation of CYP3A4 protein expression was abolished by co-treatment with the glucocorticoid receptor (GR) inhibitor, but not by co-treatment with the pregnane X receptor (PXR) inhibitor. However, treatment with PXR or constitutive androstane receptor (CAR) agonist did not lead to transcriptional activation of CYP3A4 and 2B6. Only CYP1A1 was transactivated by an aryl hydrocarbon receptor (AhR) ligand.
conclusionOur results suggest that the activities of some major DMEs (CYP3A4, UGT1A1, and UGT2B7) in HuH-7 cells are promoted by DEX treatment possibly through GR activation. However, unlike HPHs, HuH-7 cells fail to show transcriptional regulation of DMEs by PXR or CAR, which limits their suitability for evaluating DME induction potential of investigational drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.